Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galera Therapeutics filings document a clinical-stage oncology company’s material agreements, governance matters, capital structure and operating disclosures. The company’s SEC reports include 8-K events for asset transactions involving dismutase mimetics, amendments to preferred-stock terms, conversions of Series B Non-Voting Convertible Preferred Stock, pre-funded warrant exercises, and executive compensation arrangements.
Galera’s proxy and annual-meeting materials cover stockholder voting procedures, director nominations, governance requirements and related capital-structure disclosures. Its public-company records also identify GRTX common stock on the OTCQB Market and provide formal disclosure of financial results, reporting obligations, risk-related matters and corporate actions affecting the company’s oncology development business.
Galera Therapeutics approved a one-for-two hundred reverse stock split of its common stock. Every 200 existing shares will automatically convert into one share at the effective time on July 12, 2026, with split-adjusted trading expected to begin on July 13, 2026.
No fractional shares will be issued; instead, stockholders will receive cash equal to the fractional share amount multiplied by the closing price on the last trading day before effectiveness. The split will proportionally reduce shares available under the 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan and the shares issuable upon exercise of outstanding stock options and warrants, while increasing their exercise prices proportionately.
Galera Therapeutics, Inc. adopted, by written consent, an Agreement and Plan of Merger to combine with Obsidian Therapeutics under a newly formed parent (Gazelle Parent, Inc.), with a concurrent financing of approximately $350.0 million pledged to close prior to the mergers. The transactions provide for a two-step structure: (1) Merger Sub 1 merges into Obsidian, and (2) Merger Sub 2 merges into Galera, after which Galera and Obsidian will be wholly owned subsidiaries of Parent. Galera securityholders will receive Parent common stock using an exchange ratio that is subject to adjustment based on Final Galera net cash and a Galera Reverse Stock Split (approved range 1:75 to 1:200). The registration covers an estimated maximum of 36,878,144 shares of Parent common stock, including reserved shares for assumed awards and warrants. Completion is conditioned on, among other items, Nasdaq listing approval of Parent common stock and satisfaction or waiver of customary closing conditions.
Parvinder Singh Hyare filed a Schedule 13D reporting beneficial ownership of 13,521,921 shares of Galera Therapeutics common stock, representing about 6.6% of shares outstanding. This position arose from the conversion on May 15, 2026 of 13,521.292 shares of Series B Non-Voting Convertible Preferred Stock into common stock under a mandatory conversion elected by Galera’s board.
Those preferred shares were originally received in Galera’s December 2024 acquisition of Nova Pharmaceuticals, where Nova stock was exchanged into Series B Preferred at a 177.9117 exchange ratio. The filing also notes that Hyare is party to stockholder support agreements connected to Galera’s planned merger with Obsidian Therapeutics, under which holders of roughly 51.1% of Galera’s outstanding capital stock agreed to vote in favor of the proposed mergers and against competing transactions. Hyare states he may buy or sell Galera securities in the future depending on conditions but has no current specific plans beyond the agreements described.
Galera Therapeutics disclosed a proposed merger with Obsidian Therapeutics pursuant to an Agreement and Plan of Merger dated April 14, 2026. The filing includes Obsidian’s ASCO presentation reporting early clinical data for OBX-115, an ACZ-regulated mbIL15-engineered TIL therapy.
The presentation reports OBX-115 outcomes at the RP2D in 15 treated patients: an objective response rate of 67% (10/15), including 2 complete responses, a disease control rate of 93%, median study follow-up of 4.3 months, and median infused dose of 83.4×10^9 cells. Median duration of response was not reached. Safety findings disclosed cytokine release syndrome in 33% of patients and mostly Grade ≤2 treatment-related adverse events.
The filing notes that Galera and the newly formed company have filed a Form S-4 registration statement and prospectus materials relating to the proposed transaction; investors are urged to read those materials when available.
Galera Therapeutics announced a proposed merger with Obsidian Therapeutics under an Agreement and Plan of Merger dated April 14, 2026, under which Galera and Obsidian will each merge into newly formed subsidiaries of Gazelle Parent, creating a combined company. A registration statement on Form S-4 has been filed that includes a prospectus/information statement for the transaction. The Prospectus will be mailed to Galera stockholders and additional SEC filings may follow; completion is subject to the conditions in the Merger Agreement.
Emerald Bioventures, LLC and Timothy Opler filed an amended Schedule 13D reporting beneficial ownership of 61,029,978 shares of Galera Therapeutics common stock, or about 30.2% of the outstanding shares. This reflects a mandatory conversion of preferred stock into common shares.
On May 14, 2026, Galera delivered a Notice of Mandatory Conversion for its Series B Non-Voting Convertible Preferred Stock, effective May 15, 2026. In this conversion, 20,813.8186192892 shares of Series B Preferred held by Emerald were converted into 20,813,818 common shares, with cash paid in lieu of fractional shares.
After the conversion, Emerald holds only common stock and no Series B Preferred. The filing states that the ownership percentage is based on 203,268,886 common shares outstanding, combining shares previously outstanding and those issued upon conversion of all Series B Preferred Stock.
Galera Therapeutics, Inc. reported a major ownership change as a key holder converted preferred stock into common shares. On May 15, 2026, Emerald Bioventures, LLC converted 20,813.8186 shares of Galera’s Series B Non-Voting Convertible Preferred Stock into 20,813,818 shares of common stock, based on a 1,000:1 Conversion Ratio.
After this derivative conversion, Emerald directly held 61,029,978 shares of Galera common stock. No fractional common shares were issued; instead, Galera will pay Emerald cash equal to the trading value of the fractional share amount on the conversion date. The filing is made jointly by Emerald and Timothy Opler, who is the managing member of Emerald and may be deemed to beneficially own the securities held by Emerald.
Galera Therapeutics, Inc. announced a proposed merger with Obsidian Therapeutics under an Agreement and Plan of Merger dated April 14, 2026. The parties state the transaction will combine Galera and Obsidian as wholly owned subsidiaries of a newly formed parent and that a registration statement on Form S-4 (the Prospectus) has been filed to provide information to Galera stockholders.
The communication notes the Prospectus will be mailed to Galera stockholders and urges careful review of the registration statement and prospectus. It disclaims any offer or solicitation and identifies directors and officers of Galera and Obsidian as possible participants in any proxy solicitation. The filing contains customary forward-looking statements and references Galera’s prior SEC filings for risk factors.
Galera Therapeutics announced a proposed merger with Obsidian Therapeutics pursuant to an Agreement and Plan of Merger dated April 14, 2026, under which Galera will become a wholly owned subsidiary of the newly formed parent if conditions are satisfied.
Obsidian reported positive Phase 2 OBX-115 data in advanced melanoma (67% objective response rate in 15 patients at the RP2D; median follow-up 4.3 months) and plans to present incremental data at the 2026 ASCO Annual Meeting on June 1, 2026. The companies filed a Form S-4 registration statement and noted that the Prospectus will be mailed to Galera stockholders.
Galera Therapeutics, Inc. converted all remaining shares of its Series B Non-Voting Convertible Preferred Stock into common stock on May 15, 2026. The company exchanged 42,839.11 Series B preferred shares for 42,839,103 shares of common stock under the existing Certificate of Designation.
No fractional common shares were issued; instead, holders will receive cash equal to the trading value of any fractional share amounts as of the close of business on the conversion date. After this mandatory conversion, no Series B preferred shares remain issued or outstanding, simplifying Galera’s capital structure to common stock only.